Investors should buy Xylem after its acquisition of fellow water technology firm Evoqua, Goldman Sachs said. The bank reinitiated its buy rating on Xylem with a price target of $133, which implies a 24.2% upside from where the stock finished Wednesday's session.
The newly expanded company should have a better mix of public and industrials, which are both considered more stable than end markets that are mainly residential focused, he added. Meanwhile, he said valuation is more attractive following the stock's underperformance so far this year. Multiples have compressed around the historical average despite expectations for better growth and earnings upside following the deal. XYL .
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
50 stocks that hedge fund managers love now: Goldman SachsGoldman Sachs: Hedge fund managers' favorite stocks have beaten the market this year — here are the 50 companies they're most confident in right now
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »
22 stocks to buy with an average of 39% upside: Goldman SachsInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
แหล่ง: BusinessInsider - 🏆 729. / 51 อ่านเพิ่มเติม »